Highlights JW (Cayman) Therapeutics Co. Ltd

Equities

2126

KYG5210T1040

Delayed Hong Kong S.E. Other stock markets 02:55:00 21/05/2024 BST			5-day change	1st Jan Change
2.41 ^HKD	-0.41%		-6.23%	+6.64%

03-20	JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023	MT
03-20	JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023	03-20	MT
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
China Regulator Accepts JK Therapeutics' Supplemental License Application for Lymphoma Therapy	01-05	MT
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva in Patients with Relapsed or Refractory Mantle Cell Lymphoma	01-04	CI
JW Therapeutics Announces Exclusive Collaboration with 2Seventy Bio for Autoimmune Disease Car-T Therapy	01-02	CI
JW (Cayman) Therapeutics to Expand Strategic Alliance with Cell and Gene Therapy Firm	13/09/23	MT
2Seventy Bio, Inc. and Jw Therapeutics Announce Intent to Expand Strategic Partnership to Accelerate the Research and Development of T Cell-Based Immunotherapies and Autoimmune Therapies	12/09/23	CI
JW Therapeutics' H1 Attributable Loss Narrows on Higher Revenue	29/08/23	MT
JW Therapeutics Co. Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23	CI
JW (Cayman) Therapeutics to Buy Viral Vector from Substantial Shareholder	22/05/23	MT
JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus	10/04/23	CI
JW Therapeutics' 2022 Loss Widens	30/03/23	MT
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23	CI
JW Therapeutics Co. Ltd. Announces Initiation of Clinical Study of Carteyva® in First-Line Treatment in Patients with High-Risk Large B-Cell Lymphoma	08/03/23	CI
JW Therapeutics Co. Ltd Announces the Initiation of Clinical Study of JWATM214	28/02/23	CI
JW Therapeutics Co. Ltd Provides Update on Latest Clinical Data on Carteyva® in Follicular Lymphoma	12/12/22	CI
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients	09/11/22	CI
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies	27/10/22	CI
JW (Cayman) Therapeutics to Develop, Market 2seventy bio's Cell Therapy Product in China	27/10/22	MT
JW (Cayman) Gets Regulatory OK in China for Supplemental New Drug Application for Follicular Lymphoma Treatment	11/10/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights JW (Cayman) Therapeutics Co. Ltd

Equities

2126

KYG5210T1040

Highlights

Filters